Philip Morris International
PM
$188.23
-1.72%
Philip Morris International Inc. (PM) is a global tobacco company that manufactures and sells cigarettes, heated tobacco products, vapes, and oral nicotine products outside the United States, with iconic brands including Marlboro, IQOS, and Zyn. As the world's largest publicly traded tobacco company by market cap, PMI holds a dominant position in both combustible and reduced-risk product categories, leveraging its early mover advantage in heated tobacco and the 2023 acquisition of Swedish Match to lead in nicotine pouches. The current investor narrative centers on PMI's transformation toward a smoke-free future, with reduced-risk products now representing a significant portion of revenue, while the company navigates regulatory challenges, particularly FDA decisions on nicotine pouches, and maintains its status as a high-yield dividend payer. Recent attention has been driven by strong revenue growth, driven by IQOS and Zyn adoption, and the stock's outperformance relative to the broader market, despite ongoing concerns about regulatory headwinds and the long-term decline of combustible cigarette volumes.…
PM
Philip Morris International
$188.23
Related headlines
Investment Opinion: Should I buy PM Today?
Rating: Buy. PM offers a compelling mix of growth, income, and value, with a forward PE of 20.77x and a PEG of 0.36x, indicating undervaluation relative to growth. The consensus analyst target of $203.80 implies 7.0% upside, and the high target of $225 suggests 18.2% potential. Revenue growth of 9.1% YoY, gross margin of 67.1%, and operating margin of 36.7% demonstrate strong profitability. Free cash flow of $10.67B supports the dividend and buybacks. The thesis is contingent on continued reduced-risk product adoption and favorable regulatory outcomes. This Buy would upgrade to Strong Buy if the stock pulls back to below $175, or downgrade to Hold if regulatory setbacks occur or growth decelerates below 5%.
Sign up to view all
PM 12-Month Price Forecast
The AI model assesses PM as bullish with medium confidence. The company's successful transition to reduced-risk products, combined with attractive valuation metrics and strong analyst support, suggests upside potential. However, regulatory uncertainties and the high payout ratio temper confidence. Upgrades would occur if FDA approvals are granted and growth accelerates; downgrades if regulatory setbacks or margin compression emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $203.80 and implied upside of +8.3% versus the current price.
Average Target
$203.80
0 analysts
Implied Upside
+8.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $225
Analyst target range
PM is covered by 15 analysts, with a consensus recommendation leaning bullish, as evidenced by recent actions from major firms: Morgan Stanley maintains Overweight, Needham and Stifel have Buy ratings, and Citigroup also has a Buy. The average target price is $203.80, implying an upside of 7.0% from the current price of $190.39. The target range spans from a low of $175.00 to a high of $225.00, with the high target suggesting a 18.2% upside, while the low target implies a -8.1% downside. The wide spread of $50 between low and high targets indicates significant uncertainty among analysts, likely due to regulatory risks and the pace of smoke-free product adoption. Notably, Jefferies recently downgraded from Buy to Hold, reflecting some caution, but the overall sentiment remains positive, with no sell ratings among the recent actions.
Bulls vs Bears: PM Investment Factors
PM presents a balanced risk/reward profile. The bull case is anchored by accelerating revenue growth, a successful shift to reduced-risk products, and a compelling PEG ratio, while the bear case centers on regulatory risks, combustible volume declines, and valuation premium. Currently, the evidence slightly favors the bulls due to strong operational execution and analyst optimism, but the key tension is whether regulatory decisions on nicotine pouches will derail the growth engine. If FDA rulings are favorable, the stock could re-rate higher; if unfavorable, the downside could be significant.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 9.1% YoY to $10.146B, up from 6.4% growth in Q4 2025, indicating accelerating momentum driven by reduced-risk products.
- Strong Reduced-Risk Product Mix: Reduced-risk products (IQOS, Zyn) contributed $4.379B in Q1 2026, representing 43.2% of total revenue, showcasing successful portfolio transformation.
- Attractive Valuation on PEG: PEG ratio of 0.36x suggests undervaluation relative to growth, as a PEG below 1 typically indicates the stock is trading below its growth-adjusted fair value.
- High Dividend Yield with Growth: Dividend yield of 3.46% combined with revenue growth and a payout ratio of 76% provides income plus capital appreciation potential.
Bearish
- Regulatory Overhang on Nicotine Pouches: FDA decisions on nicotine pouches could impact Zyn's growth, as highlighted by recent news on market share defense and potential restrictions.
- Combustible Volume Decline: Traditional cigarette volumes continue to decline, with combustible products still accounting for 56.8% of revenue, posing a long-term drag.
- High Valuation vs. Peers: Trailing PE of 22.06x and EV/EBITDA of 16.81x are at a premium to historical averages, leaving limited margin for error.
- Negative Relative Strength: PM underperformed the S&P 500 over 1-year (-5.17% relative) and 6-month (-12.33% relative), indicating weaker momentum compared to the broader market.
PM Technical Analysis
PM is in a sustained uptrend, with the stock price of $190.39 as of August 14, 2026, reflecting a 15.2% gain over the past year. The current price sits at 78.6% of its 52-week range (between $142.11 low and $207.76 high), indicating the stock is trading closer to its highs, which suggests strong momentum but also potential overextension. The 52-week high of $207.76 was reached in late July 2026, and the stock has since pulled back slightly, yet remains well above its 52-week low, signaling a healthy uptrend with occasional corrections.
Beta
0.40
0.40x market volatility
Max Drawdown
-20.0%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+7.9%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +2.5% |
| 3m | -0.4% | +2.7% |
| 6m | +2.6% | +11.1% |
| 1y | +7.9% | +20.5% |
| ytd | +17.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue trajectory is solidly growing, with the most recent quarter (Q1 2026) reporting revenue of $10.146 billion, a 9.1% year-over-year increase. This growth is accelerating, as Q1 2026's growth rate of 9.1% compares favorably to the 6.4% growth seen in Q4 2025 (revenue of $10.362 billion vs. $9.706 billion in Q4 2024). The growth is driven by reduced-risk products, which contributed $4.379 billion in revenue (43.2% of total), while combustible products still account for the majority at $5.767 billion. The strong performance of IQOS and Zyn is offsetting declines in traditional cigarette volumes, supporting the investment thesis of a successful transition.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Given PM's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 22.06x, while the forward PE is 20.77x, indicating the market expects earnings growth of approximately 6.2% over the next year. The gap between trailing and forward PE suggests moderate growth expectations, which is consistent with PM's stable but not explosive earnings outlook. The PEG ratio of 0.36x implies that the stock is undervalued relative to its growth rate, as a PEG below 1 typically indicates undervaluation.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of -4.89 (negative equity due to buybacks), which amplifies financial leverage and interest expense ($237M in Q1 2026). The payout ratio of 76% limits dividend growth flexibility, and free cash flow of $10.67B TTM must cover both dividends and debt obligations. Revenue concentration in combustible products (56.8%) exposes PM to secular decline, though reduced-risk products are growing to offset this. Earnings volatility is moderate, with Q4 2024 net loss of -$579M due to impairments, but recent quarters show recovery.
FAQ
The key risks are: 1) Regulatory risk: FDA decisions on nicotine pouches could restrict Zyn's growth, as seen in recent news. 2) Financial risk: High debt levels (debt-to-equity -4.89) and a payout ratio of 76% limit financial flexibility. 3) Market risk: The stock's beta of 0.4 suggests lower volatility, but it underperformed the S&P 500 over the past year, indicating potential sector rotation. 4) Company-specific risk: Combustible volume declines could accelerate, impacting revenue. The most severe risk is a regulatory crackdown on reduced-risk products, which could lead to a -25% downside to the 52-week low.
The 12-month forecast is moderately bullish. The base case (50% probability) targets $195-$210, aligning with the analyst average of $203.80. The bull case (30% probability) targets $210-$225, driven by favorable FDA decisions and accelerated growth. The bear case (20% probability) targets $160-$175, if regulatory setbacks occur. The most likely scenario is the base case, assuming steady growth and no major regulatory shocks. Key assumptions include continued reduced-risk product adoption and stable margins.
PM appears undervalued relative to its growth prospects. The trailing PE of 22.06x is slightly above the market average, but the PEG of 0.36x indicates that the market is not fully pricing in the expected earnings growth. The forward PE of 20.77x is reasonable for a company with 9.1% revenue growth and strong margins. Compared to peers, PM trades at a premium to traditional tobacco companies but at a discount to high-growth consumer staples. The market expects moderate growth, but if reduced-risk products continue to gain traction, the stock could re-rate higher.
PM is a good buy for investors seeking a balanced risk/reward. The stock offers a 3.46% dividend yield, a PEG of 0.36x, and analyst consensus upside of 7.0% to $203.80. However, regulatory risks on nicotine pouches and a high payout ratio are key concerns. For long-term investors with a 3-5 year horizon, the growth in reduced-risk products and attractive valuation make it a compelling addition. For short-term traders, the stock's low beta (0.4) and recent momentum may offer limited volatility, but the potential for regulatory catalysts could provide trading opportunities.
PM is more suitable for long-term investment due to its defensive nature, high dividend yield, and growth potential in reduced-risk products. The stock's low beta (0.4) and stable earnings make it a good fit for income-focused portfolios. Short-term trading is possible, given the stock's recent momentum and potential regulatory catalysts, but the low volatility may limit short-term gains. A minimum holding period of 3-5 years is recommended to fully capture the benefits of the smoke-free transition and dividend compounding.